Chia-chih Kuo

Tainan, TNQ, Taiwan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications

Clinical outcomes of lean metabolic dysfunction-associated steatotic liver disease by phenotypic subtypes.

Clinical outcomes of lean metabolic dysfunction-associated steatotic liver disease by phenotypic subtypes.

Journal: Journal of gastroenterology
Published: May 19, 2026

Direct-acting antiviral therapy is associated with a reduced risk of selected immune-mediated inflammatory diseases in chronic hepatitis C infection: A real-world cohort study.

Direct-acting antiviral therapy is associated with a reduced risk of selected immune-mediated inflammatory diseases in chronic hepatitis C infection: A real-world cohort study.

Journal: PloS one
Published: March 26, 2026

Clinical benefits of tirzepatide in patients with steatotic liver disease and cardiometabolic dysfunction.

Clinical benefits of tirzepatide in patients with steatotic liver disease and cardiometabolic dysfunction.

Journal: Communications medicine
Published: October 19, 2025

Exploring the Relationship Between Cerebral Blood Flow and Oral Exercise Using Head-Mounted Near-Infrared Spectroscopy.

Exploring the Relationship Between Cerebral Blood Flow and Oral Exercise Using Head-Mounted Near-Infrared Spectroscopy.

Journal: Dysphagia
Published: September 10, 2025

Comparative effectiveness of empagliflozin versus dapagliflozin in adults with metabolic dysfunction-associated steatotic liver disease.

Comparative effectiveness of empagliflozin versus dapagliflozin in adults with metabolic dysfunction-associated steatotic liver disease.

Journal: Frontiers in endocrinology
Published: July 20, 2025

Super effect or methodological flaw: questioning the glucagon-like peptide-1 receptor agonist cancer narrative. Reply to Maier GA, Rathmann W, Kuß O [letter].

Super effect or methodological flaw: questioning the glucagon-like peptide-1 receptor agonist cancer narrative. Reply to Maier GA, Rathmann W, Kuß O [letter].

Journal: Diabetologia
Published: July 14, 2025

Editorial: Beyond Clinical Trials-Real-World Data Suggest Usefulness of GLP-1 RAs in MASLD Treatment. Authors' Reply.

Editorial: Beyond Clinical Trials-Real-World Data Suggest Usefulness of GLP-1 RAs in MASLD Treatment. Authors' Reply.

Journal: Alimentary pharmacology & therapeutics
Published: February 17, 2025

Comparing clinical outcomes of adults with obesity receiving tirzepatide versus bariatric metabolic surgery: A multi-institutional propensity score-matched study.

Comparing clinical outcomes of adults with obesity receiving tirzepatide versus bariatric metabolic surgery: A multi-institutional propensity score-matched study.

Journal: Diabetes, obesity & metabolism
Published: February 03, 2025

Semaglutide versus other GLP-1 receptor agonists in patients with MASLD.

Semaglutide versus other GLP-1 receptor agonists in patients with MASLD.

Journal: Hepatology communications
Published: November 30, 2024

Glucagon-like peptide-1 receptor agonists and gastrointestinal cancer risk in individuals with type 2 diabetes.

Glucagon-like peptide-1 receptor agonists and gastrointestinal cancer risk in individuals with type 2 diabetes.

Journal: Diabetologia
Published: November 27, 2024

Impact of GLP-1 Receptor Agonists on Alcohol-Related Liver Disease Development and Progression in Alcohol Use Disorder.

Impact of GLP-1 Receptor Agonists on Alcohol-Related Liver Disease Development and Progression in Alcohol Use Disorder.

Journal: Alimentary pharmacology & therapeutics
Published: November 26, 2024

A retrospective analysis of combination therapy with GLP-1 receptor agonists and SGLT2 inhibitors versus SGLT2 inhibitor monotherapy in patients with MASLD.

A retrospective analysis of combination therapy with GLP-1 receptor agonists and SGLT2 inhibitors versus SGLT2 inhibitor monotherapy in patients with MASLD.

Journal: Nature communications
Published: November 25, 2024
Showing 1-12 of 17

Last Updated: 09/26/2026